synthetic peptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-07-20. Anything still debated is marked as such rather than presented as settled.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
239Pu(16O,xn)255−xNo This reaction was first studied in 1958 at the FLNR. The team were able to measure ~8.8 MeV alpha particles with a half-life of 30 s and assigned to253,252,251102. A repeat in 1960 was unsuccessful and it was concluded the first results were probably associated with background effects.
Rattlesnakes do not generally have bright or showy colors (reds, yellows, blues, etc.), instead relying on subtle earth tones that resemble the surrounding environment. Creases in the epidermal tissue connect the scales of rattlesnakes. When ingesting large prey, these creases can unfold, allowing the skin to expand to envelop a much greater volume. The skin appears to tightly stretch to accommodate the meal, but in reality, the skin is simply smoothing out from its creased state and is not under very high tension.
Liu Wencai's administration was notorious for its corruption but effective in achieving Liu Wenhui's goals, collecting 30,000 silver dollars in its first year through the enforcement of various taxes. Liu Wencai also advised his brother to appoint loyalists as county magistrates in areas under their control, ensuring local revenue flowed directly to his forces. In Yibin, Liu Wenhui promoted modern education in both the military and civilian spheres. Also in 1922, Liu Xiang, who had become Sichuan governor, was defeated in a war against Xiong Kewu and Deng Xihou. Liu Wenhui moved his troops to Chongqing to support his nephew, but after Liu Xiang's defeat, he negotiated a withdrawal back to Yibin to avoid the loss of his army. Liu Xiang was subsequently forced to resign his position as governor. From 1922 to 1924, there was constant conflict in Sichuan. According to historian Robert Kapp, the region functioned as a politically isolated ecosystem for much of the early Republican period. Because it was insulated by geography from the rest of China, this allowed a highly fragmented and fluid balance of power to emerge against local warlords. Outside powers, including Wu Peifu of the Zhili Clique and Sun Yat-sen of the Kuomintang, also intervened intermittently in the Sichuan melee to support their chosen side in the larger context of the North-South conflict. Liu Wenhui was generally aligned with Liu Xiang and Liu Chengxun during this period, being promoted to commander of the Ninth Division in February 1923 by Liu Chengxun.
Fixed trials consider existing data only during the trial's design, do not modify the trial after it begins, and do not assess the results until the study is completed. Adaptive clinical trials use existing data to design the trial, and then use interim results to modify the trial as it proceeds. Modifications include dosage, sample size, drug undergoing trial, patient selection criteria and "cocktail" mix. Adaptive trials often employ a Bayesian experimental design to assess the trial's progress. In some cases, trials have become an ongoing process that regularly adds and drops therapies and patient groups as more information is gained. The aim is to more quickly identify drugs that have a therapeutic effect and to zero in on patient populations for whom the drug is appropriate. Clinical trials are conducted typically in four phases, with each phase using different numbers of subjects and having a different purpose to construct focus on identifying a specific effect.
This was first done for lysozyme, an enzyme found in tears, saliva and egg whites that digests the coating of some bacteria; the structure was solved by a group led by David Chilton Phillips and published in 1965. This high-resolution structure of lysozyme marked the beginning of the field of structural biology and the effort to understand how enzymes work at an atomic level of detail.
Sources: en.wikipedia.org
== See also == Golden Crescent Golden Triangle History of Jardine, Matheson & Co. Illegal drug trade in Colombia Mexican drug war Nabidh Opium dollar Opium replacement Protocol for Limiting and Regulating the Cultivation of the Poppy Plant, the Production of, International and Wholesale Trade in, and Use of Opium Psychoactive drug Society for the Suppression of the Opium Trade Morphine Heroin
Laurence Fox is charged with a sexual offence after allegedly sharing an intimate image of television star Narinder Kaur without her consent. 26 March – Chancellor Rachel Reeves will deliver the March 2025 United Kingdom spring statement to the House of Commons. 28 March – Matthew Doyle announces he is stepping down as Downing Street Director of Communications. Sinn Féin councillor Cathal King is suspended for two months from Newry, Mourne and Down District Council by the Northern Ireland Local Government Commission for Standards for being drunk in charge of a car. 28–29 March – 2025 Alba Party leadership election 29 March – BBC News reports that Amanda Spielman, who was chief inspector of Ofsted at the time Ruth Perry committed suicide following a poor Ofsted assessment, has been nominated for a peerage by Conservative leader Kemi Badenoch. Three Bolsover District Councillors resign from the Labour Party in protest at Keir Starmer's leadership, and will sit as independents. 30 March – Downing Street sources tell the BBC the UK would not hesitate to retaliate against US tariffs if required. Talks are held between the prime minister and US president, which are subsequently described as "constructive".
As of September 11, 2017, Teva remained the "world's biggest seller of generics medicines." On September 11, 2017, it was reported that they had selected Kåre Schultz as the new Teva CEO. A day later the company announced it would sell its Paragard contraceptive brand to Cooper Cos for $1.1 billion, with the funds being used to pay down debt. Days later the company announced further divestments: a sale of contraception, fertility, menopause and osteoporosis products to CVC Capital Partners Fund VI for $703 million and its emergency contraception brands for $675 million to Foundation Consumer Healthcare. By December, the company had announced a drastic 25 percent workforce reduction (greater than 14,000 employees) as part of a two-year cost-reduction strategy. Following considerable lobbying by the Israeli Government, from whom Teva received considerable tax breaks, and from Israel's labor federation, the Histadrut, Teva agreed to delay some of the layoffs in Israel. In October 2019, Teva faced criticism for making a "business decision to discontinue the drug" Vincristine, essential for the treatment of most childhood cancers according to the Food and Drug Administration.
== Functions == Riboflavin is essential to the formation of two major coenzymes, FMN and FAD. These coenzymes are involved in energy metabolism, cell respiration, antibody production, growth and development. Riboflavin is essential for the metabolism of carbohydrates, protein and fats. FAD contributes to the conversion of tryptophan to niacin (vitamin B3) and the conversion of vitamin B6 to the coenzyme pyridoxal 5'-phosphate requires FMN. Riboflavin is involved in maintaining normal circulating levels of homocysteine; in riboflavin deficiency, homocysteine levels increase, elevating the risk of cardiovascular diseases.
Unlike terrestrial silos that maintain value for decades, the imminent expiration of orbital weapons creates a fiscal “use it or lose it" pressure, potentially incentivizing commanders to expend these assets in gray zone conflicts rather than allowing billions of dollars of hardware to burn up in the atmosphere. Ultimately, the deployment of such systems creates a state of "orbital ambiguity" that destabilizes traditional deterrence. Because a Starshield satellite carrying defensive interceptors is indistinguishable on radar from a commercial Starlink satellite or one carrying offensive hypersonic gliders, adversaries are forced to treat the entire constellation as a potential nuclear-equivalent first-strike platform. Strategic theorists such as Forrest Morgan (RAND) and James Acton (Carnegie Endowment) argue that this "warhead ambiguity" creates a “reciprocal fear of surprise attack," incentivizing adversaries to execute massive "blinding" strikes against the constellation or its launch infrastructure at the onset of any crisis, thereby ensuring that a limited conflict immediately escalates to the strategic level.
Sources: en.wikipedia.org
A more plausible alternative for the evolutionary origins of this system is through constructive neutral evolution, where the order of steps is reversed, with the gratuitous capacity for editing preceding the "defect".
Other bands that have been influenced by Alice in Chains include 10 Years, Avenged Sevenfold, Breaking Benjamin, Bush, Creed, Dallas Green, Days of the New, Disturbed, Hoobastank, Incubus, Korn, Manic Street Preachers, Mudvayne, Nickelback, A Pale Horse Named Death, Puddle of Mudd, Queens of the Stone Age, Rains, Seether, Skunk Anansie, Smile Empty Soul, Stone Sour, Tantric, Taproot, and Theory of a Deadman. Metallica said they have always wanted to tour with the band, citing Alice in Chains as a major inspiration for their 2008 release, Death Magnetic. Alice in Chains has also had a significant influence on modern heavy metal. Their songs were covered by various metal bands such as In Flames, Opeth, Dream Theater, Secrets of the Moon, Suicide Silence, 36 Crazyfists, Cane Hill, Ektomorf, Dritt Skitt, Grave and Thou, who described their 2018 EP Rhea Sylvia as "a melodic grunge, Alice in Chains homage." In 2009, Anders Fridén of Swedish melodic death metal band In Flames cited Layne Staley as an inspiration for his vocals on the band's later albums. In addition to fellow musicians, the band has also received praise from critics, with Steve Huey calling them "one of the best metal bands of the '90s" upon reviewing the 1999 compilation Nothing Safe. In 2009, the Vitamin String Quartet released the album The String Quartet Tribute to Alice in Chains, featuring instrumental versions on viola, violin and cello of 12 of the band's biggest hits.
As it contains Lactobacillus bacteria, kefir can be used to make a sourdough starter. It is also useful as a buttermilk substitute in baking. Kefir is one of the main ingredients in cold borscht soup in Lithuania, also known in Poland as Lithuanian cold soup (chłodnik litewski), and other countries. The kefir-based soup okroshka is common across the former Soviet Union. Kefir may be used in place of milk on cereal, granola, milkshakes, salad dressing, ice cream, smoothies and soup. In Estonia, kefir is also often mixed with kama and eaten as a snack or a quick breakfast.
== General sources == Aniszewski, Tadeusz (2007). Alkaloids: secrets of life. Amsterdam: Elsevier. ISBN 978-0-444-52736-3. Begley, Tadhg P. (2009). Encyclopedia of Chemical Biology. Vol. 10. Wiley. pp. 1569–1570. doi:10.1002/cbic.200900262. ISBN 978-0-471-75477-0. Brossi, Arnold (1989). The Alkaloids: Chemistry and Pharmacology. Academic Press. Dewick, Paul M. (2002). Medicinal Natural Products: A Biosynthetic Approach (Second ed.). Wiley. ISBN 978-0-471-49640-3. Fattorusso, E.; Taglialatela-Scafati, O. (2008). Modern Alkaloids: Structure, Isolation, Synthesis and Biology. Wiley-VCH. ISBN 978-3-527-31521-5. Grinkevich NI; Safronich LN, eds. (1983). The chemical analysis of medicinal plants (in Russian). Moscow: Vysshaya Shkola. Hesse, Manfred (2002). Alkaloids: Nature's Curse or Blessing?. Wiley-VCH. ISBN 978-3-906390-24-6. Knunyants, IL (1988). Chemical Encyclopedia. Soviet Encyclopedia. Orekhov, AP (1955). Chemistry alkaloids (Acad. 2nd ed.). Moscow.{{cite book}}: CS1 maint: location missing publisher (link) Plemenkov, VV (2001). Introduction to the Chemistry of Natural Compounds. Kazan.{{cite book}}: CS1 maint: location missing publisher (link) Saxton, J. E. (1971). The Alkaloids: A Specialist Periodical Report. London: The Chemical Society. Veselovskaya, N. B.; Kovalenko, A. E. (2000). Drugs. Moscow: Triada-X. Wink, M (2009). "Mode of action and toxicology of plant toxins and poisonous plants". Mitt. Julius Kühn-Inst. 421: 93–112x.
On 11 January 1922, Leonard Thompson, a 14-year-old diabetic who lay dying at the Toronto General Hospital, was given the first injection of insulin. However, the extract was so impure that Thompson had a severe allergic reaction, and further injections were cancelled. Over the next 12 days, Collip worked day and night to improve the ox-pancreas extract. A second dose was injected on 23 January, eliminating the glycosuria that was typical of diabetes without causing any obvious side-effects. The first American patient was Elizabeth Hughes, the daughter of U.S. Secretary of State Charles Evans Hughes. The first patient treated in the U.S. was future woodcut artist James D. Havens; John Ralston Williams imported insulin from Toronto to Rochester, New York, to treat Havens. Banting and Best never worked well with Collip, regarding him as something of an interloper, and Collip left the project soon after. Over the spring of 1922, Best managed to improve his techniques to the point where large quantities of insulin could be extracted on demand, but the preparation remained impure. The drug firm Eli Lilly and Company had offered assistance not long after the first publications in 1921, and they took Lilly up on the offer in April. In November, Lilly's head chemist, George B. Walden discovered isoelectric precipitation and was able to produce large quantities of highly refined insulin. Shortly thereafter, insulin was offered for sale to the general public.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.